News & Updates

For patients with type 2 diabetes (T2D) and metabolic dysfunction-associated steatotic liver disease (MASLD) cirrhosis, treatment with glucagon-like peptide-1 receptor agonists helps reduce the risk of hepatic decompensation, portal hypertension, hepatocellular carcinoma, and liver transplantation, according to a study.

Clinicians may favour prescribing sodium-glucose cotransporter 2 (SGLT2) inhibitors to patients with both type 2 diabetes (T2D) and nonalcoholic fatty liver disease (NAFLD), with the drugs having potential benefits in terms of NAFLD regression and reduced incidences of adverse liver-related outcomes, according to a study.

Treatment with plozasiran, an experimental small interfering–RNA drug that targets apolipoprotein C3 (APOC3) gene, helps regulate triglyceride levels, bringing them below the critical threshold associated with acute pancreatitis for most patients with severe hypertriglyceridemia, according to the phase IIb SHASTA-2* study.

A recent study suggests that adopting a healthy diet does protect against the risk of developing type 2 diabetes (T2D) among people with habitual short sleep duration, according to a study.

Testosterone replacement therapy in men with hypogonadism does not appear to reduce the risk of developing diabetes, according to the results of the TRAVERSE* substudy.